Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $154
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Eric Coldwell maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $153 to $154.
July 24, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Baird analyst Eric Coldwell maintains a Neutral rating on Quest Diagnostics and raises the price target from $153 to $154.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. The slight increase in the price target from $153 to $154 indicates a marginally positive outlook but not enough to change the overall rating.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100